These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 18854763

  • 1. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
    Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V.
    J Hypertens; 2008 Nov; 26(11):2213-9. PubMed ID: 18854763
    [Abstract] [Full Text] [Related]

  • 2. Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus.
    Kihm LP, Hinkel UP, Michael K, Sommerer C, Seckinger J, Morath C, Zeier M, Schwenger V.
    Transplantation; 2009 Jul 27; 88(2):261-5. PubMed ID: 19623023
    [Abstract] [Full Text] [Related]

  • 3. The influence of calcineurin inhibitors on pulse wave velocity in renal transplant recipients.
    Strózecki P, Adamowicz A, Włodarczyk Z, Manitius J.
    Ren Fail; 2007 Jul 27; 29(6):679-84. PubMed ID: 17763162
    [Abstract] [Full Text] [Related]

  • 4. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 5. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression.
    Martínez-Castelao A, Sarrias X, Bestard O, Gil-Vernet S, Serón D, Cruzado JM, Moreso F, Díez-Noguera A, Grinyó JM.
    Transplant Proc; 2005 Nov 15; 37(9):3788-90. PubMed ID: 16386539
    [Abstract] [Full Text] [Related]

  • 6. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
    Roos M, Liu S, Strobl M, Schmaderer C, Baumann M, Heemann U, Lutz J.
    Transplant Proc; 2008 Dec 15; 40(10):3731-6. PubMed ID: 19100477
    [Abstract] [Full Text] [Related]

  • 7. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 8. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 9. Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.
    Kälble F, Seckinger J, Schaier M, Morath C, Schwenger V, Zeier M, Sommerer C.
    Clin Transplant; 2017 Aug 15; 31(8):. PubMed ID: 28581202
    [Abstract] [Full Text] [Related]

  • 10. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 11. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups.
    Transpl Int; 2007 Jan 20; 20(1):27-36. PubMed ID: 17181650
    [Abstract] [Full Text] [Related]

  • 12. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.
    Montagnino G, Sandrini S, Iorio B, Schena FP, Carmellini M, Rigotti P, Cossu M, Altieri P, Salvadori M, Stefoni S, Corbetta G, Ponticelli C.
    Nephrol Dial Transplant; 2008 Feb 20; 23(2):707-14. PubMed ID: 17890244
    [Abstract] [Full Text] [Related]

  • 13. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.
    Teutonico A, Schena PF, Di Paolo S.
    J Am Soc Nephrol; 2005 Oct 20; 16(10):3128-35. PubMed ID: 16107580
    [Abstract] [Full Text] [Related]

  • 14. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb 20; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 15. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
    Transplant Proc; 2006 Sep 20; 38(7):2032-4. PubMed ID: 16979990
    [Abstract] [Full Text] [Related]

  • 16. Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients.
    Cohen DL, Warburton KM, Warren G, Bloom RD, Townsend RR.
    Am J Hypertens; 2004 Mar 20; 17(3):209-12. PubMed ID: 15001192
    [Abstract] [Full Text] [Related]

  • 17. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L.
    Liver Transpl; 2006 Nov 20; 12(11):1640-8. PubMed ID: 16598777
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.
    Clin Transplant; 2007 Nov 20; 21(4):460-5. PubMed ID: 17645704
    [Abstract] [Full Text] [Related]

  • 19. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results.
    Masetti M, Rompianesi G, Montalti R, Romano A, Spaggiari M, Ballarin R, Guerrini GP, Gerunda GE.
    Transplant Proc; 2008 Nov 20; 40(6):1947-9. PubMed ID: 18675097
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of cyclosporine and tacrolimus on arterial function.
    Seibert F, Behrendt C, Schmidt S, van der Giet M, Zidek W, Westhoff TH.
    Transpl Int; 2011 Jul 20; 24(7):708-15. PubMed ID: 21569126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.